Catalyst Pharmaceuticals Inc’s filing revealed that its Chief Med. & Reg. Officer INGENITO GARY unloaded Company’s shares for reported $4.74 million on May 13 ’25. In the deal valued at $23.68 per share,200,000 shares were sold. As a result of this transaction, INGENITO GARY now holds 68,873 shares worth roughly $1.71 million.
Then, INGENITO GARY sold 44,000 shares, generating $1,039,720 in total proceeds. Upon selling the shares at $23.63, the Chief Med. & Reg. Officer now owns 68,873 shares.
Before that, INGENITO GARY bought 44,000 shares. Catalyst Pharmaceuticals Inc shares valued at $1,039,720 were divested by the Officer at a price of $23.63 per share.
Robert W. Baird initiated its Catalyst Pharmaceuticals Inc [CPRX] rating to an Outperform in a research note published on February 04, 2025; the price target was $28. A number of analysts have revised their coverage, including Stephens’s analysts, who began to cover the stock in mid November with a ‘”an Overweight”‘ rating. Citigroup began covering CPRX with “Buy” recommendation on March 14, 2024. BofA Securities started covering the stock on March 07, 2024. It rated CPRX as “a Buy”.
Price Performance Review of CPRX
On Tuesday, Catalyst Pharmaceuticals Inc [NASDAQ:CPRX] saw its stock jump 1.43% to $24.84. Over the last five days, the stock has gained 0.85%. Catalyst Pharmaceuticals Inc shares have risen nearly 19.02% since the year began. Nevertheless, the stocks have risen 53.90% over the past one year. While a 52-week high of $26.16 was reached on 03/24/25, a 52-week low of $14.75 was recorded on 01/08/25. SMA at 50 days reached $23.58, while 200 days put it at $21.90.
Levels Of Support And Resistance For CPRX Stock
The 24-hour chart illustrates a support level at 24.54, which if violated will result in even more drops to 24.24. On the upside, there is a resistance level at 25.07. A further resistance level may holdings at 25.30. The Relative Strength Index (RSI) on the 14-day chart is 59.17, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.50, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 3.81%. Stochastics %K at 93.56% indicates the stock is a selling.
The most recent change occurred on December 21, 2023 when Oppenheimer began covering the stock and recommended ‘”an Outperform”‘ rating along with a $30 price target.
